Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.

Javed Butler,Milton Packer,Tariq Jamal Siddiqi,Michael Böhm,Martina Brueckmann,James L Januzzi,Subodh Verma,Ingrid Gergei,Tomoko Iwata,Christoph Wanner,João Pedro Ferreira,Stuart J Pocock,Gerasimos Filippatos,Stefan D Anker,Faiez Zannad

Journal of the American College of Cardiology（2023）

引用 1|浏览31

暂无评分

摘要

The benefit of empagliflozin on major heart failure events was not influenced by KDIGO categories. The magnitude of the renal effects of the drug depended on the approach used to calculate eGFR slopes.

查看译文

关键词

cardiovascular disease, chronic kidney disease, congestive heart failure, KDIGO category, SGLT2 inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要